Abstract: The invention relates to a thermoreversible oil-in-water emulsion comprising: a TLR4 agonist, the chemical structure of which does not comprise a sugar ring, squalene, a nonionic surfactant belonging to the polyoxyethylene alkyl ether chemical group, a hydrophilic surfactant, an aqueous solvent, and which shows immunostimulating properties.

Abstract: A production method for making powder cosmetics having improved characteristics. The method includes mixing a powder component and an oil component as a binder using a mixing apparatus. The mixing apparatus is a facing rotor type mixing apparatus having a first rotor with a plurality of blades and a second rotor with a plurality of blades in a mixing chamber. The first rotor and the second rotor face each other and have rotating shafts on the same axis line. In the facing rotor type mixing apparatus, raw materials are fed into an introduction opening on a first rotor side. The raw materials are mixed by rotating the first rotor and the second rotor in the same or opposite directions to each other, and the mixed raw materials are discharged from a discharge opening on a second rotor side.

Abstract: A solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N x an amount of flavouring; and (g) optionally N×an amount of sweetener, where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.

Abstract: The present invention is directed towards a composition comprising, in a cosmetically acceptable carrier, at least one silicone-organic polymer hybrid compound; at least one nonionic film forming polymer; at least one amphoteric film forming polymer; and a neutralizer. The present invention also relates to methods for imparting shape to or maintaining the shape of hair wherein the composition provides style memory, strong hold and good shine, while at the same time, providing smoothness and a natural feel to the hair.

Abstract: The invention presented in this application relates to a fragrance deposition system for high surfactant applications such as shampoo and body wash. The system will provide a long lasting release of the fragrance and is more efficient at low levels and does not deposit particles that can cause adverse properties.

Abstract: A method for inhibiting dentinal hypersensitivity by applying a dentinal hypersensitivity inhibitor on a dentin surface. The dentinal hypersensitivity inhibitor contains at least one tetracalcium phosphate particle, an alkali metal salt of phosphoric acid, and at least one acidic calcium phosphate particle. The tetracalcium phosphate particle has an average particle diameter of 0.5 to 40 ?m. The dentinal hypersensitivity inhibitor contains a blended amount of the tetracalcium phosphate particle of 5 to 55 parts by weight relative to 100 parts by weight of a whole amount of the dentinal hypersensitivity inhibitor and a blended amount of the alkali metal salt of phosphoric acid of 1 to 100 parts by weight relative to 100 parts by weight of the tetracalcium phosphate particle.

Abstract: In one embodiment, a liquid or flowable cleansing or skin treatment composition is described which is substantially nonaqueous and which has a continuous and a discontinuous phase. Components of the discontinuous phase can chemically react with each other or with water when water is blended with the nonaqueous cleansing or skin treatment composition during consumer use. In a second embodiment, a solidified cleansing or skin treatment composition is described which contains components that can chemically react with each other or with water when water is blended with the solidified cleansing composition during consumer use. Methods for treating the skin with the inventive compositions are also described.

Abstract: Disclosed is a bolus comprising: a bolus body comprising a matrix material and one or more biologically beneficial substances contained in and/or on the matrix; wherein the exterior surface of the bolus body is shaped so as to have a least one recessed portion; and at least part of the recessed portion of the bolus body is coated with a material which retards or inhibits release of the beneficial substance(s) from the matrix.

Abstract: A microencapsulated formulation of pendimethalin comprising an alkali or an alkaline earth metal salt of an organic acid. Also described are processes for the preparation of the formulation and a method of controlling weeds at a location by using the described formulation.

Abstract: The present invention provides an orally-disintegrating solid preparation such as a tablet produced by tabletting fine granules showing controlled release of a pharmaceutically active ingredient and an additive, and the like, and the orally-disintegrating solid preparation containing fine granules coated with a coating layer containing a polymer affording a casting film having an elongation at break of about 100-about 700%. With the preparation, breakage of fine granules during tabletting can be suppressed in the production of an orally-disintegrating solid preparation containing fine granules showing controlled release of a pharmaceutically active ingredient.

Abstract: Disclosed are salts and crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof. Also disclosed are at least one pharmaceutical composition comprising at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide, at least one method of using at least one crystalline form of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide to treat cancer and/or other proliferative diseases, and processes to prepare crystalline forms of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide and salts thereof.

Abstract: Described are hair fixative compositions comprising an aqueous dispersion comprising an ethylene acrylic acid co-polymer, and optionally a metallocene catalyzed polyolefin.

Abstract: The present disclosure is directed to methods and compositions for ameliorating, preventing and treating central nervous system (CNS) disorders. The invention aims to treat subjects suffering from, susceptible to, or diagnosed with CNS disorders, and in particular, to treating patients suffering from those disorders which are associated with neurotransmitter system dysfunction.

Abstract: In order to provide a product that is suitable as fat substitute in foods, which can be produced simply and inexpensively and is deemed safe from the nutritional physiology viewpoint and with which the typical texture of fat-containing foods can be simulated as favorably as possible, particles of collagen material are proposed which are substantially insoluble and swellable in water, wherein in swollen state the particles have an average diameter of less than approximately 150 ?m. A process for the production of this product is additionally proposed.

Abstract: A hygiene tissue (1), such as a wet wipe, dry wipe, washcloth, patch, towelette, napkin, and the like includes a microbe-inhibiting composition (8). The microbe-inhibiting composition (8) includes an extracellular product of at least one probiotic bacterium and at least one additive in the form of an organic acid, with at least one of its pKa value not exceeding 5.5, and/or a salt thereof.

Abstract: Provided are cosmetic preparations for topical application containing nanocrystals of cosmetic actives leading to an increased bioactivity of the molecules in the skin and methods of making the cosmetic preparations. The nanocrystals can be added to any cosmetic topical formulation, e. g. creams, lotions and liposomal dispersions. The drug nanocrystals are produced by a combination process of low energy pearl milling followed by a high energy high-pressure homogenization leading to nanocrystal suspensions (nanosuspensions) of improved physical stability.

Abstract: A method for preparing porous microparticles containing phytosterol, by preparing a homogeneous melt of phytosterol and a partially water soluble component, cooling the melt to obtain an amorphous solid material, processing the material into a fine powder, and bringing the powder into contact with an aqueous phase under stirring conditions. A composition suitable for preparing a porous microparticle containing phytosterol. A porous microparticle containing phytosterol. A pharmaceutical or food product useful for lowering the cholesterol level in blood.

Abstract: This invention is based upon the discovery that a mixture of ethyl lactate and isoamyl lactate can be used to improve the penetration of active ingredients in skin care formulations through the outer layers of the stratum corneum and viable epidermis and into the dermis layer of the skin structure. The present invention more specifically discloses a method of rejuvenating skin comprising topically applying a topical formulation to the skin, wherein the topical formulation is comprised of ascorbic acid, an amino acid selected from the group consisting of phenylalanine and tyrosine, a non-toxic zinc salt, carnosic acid, ?-tocopherol, 0.01 weight percent to 20 weight percent of a mixture of ethyl lactate and isoamyl lactate, wherein the weight ratio of the ethyl lactate to the isoamyl lactate is within the range of 1:10 to 20:1, and a pharmaceutically acceptable carrier.

Abstract: The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone.

Abstract: The present invention provides solution to the problem involved in delivery of active molecules to nucleus. More particularly, the invention provides intrinsically fluorescent and inherently surface functionalized carbon nanospheres which are non-toxic. Also, these carbon nanospheres [CSP] were adsorbed with CTPB [CSP-CTPB] and the adsorbed CSP-CTPB are permeable to cells with nuclear targeting ability. In addition, the present invention provides a composition, a process to prepare the composition comprising CSP with adsorbed active/therapeutic molecules. Further, the instant invention provides a method for delivering active molecules inside a cell nucleus.